BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clini

Robust COVID-19 related mailback order activity; Playing a key role in COVID-19 vaccine programs in Retail and Long-Term Care Settings

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral transport medium (VTM) to support Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system.

Orchard Therapeutics today outlined nine upcoming presentations from its neurodegenerative portfolio to be featured at the 17th Annual WORLDSymposium™ being held on February 8-12, 2021

Live webcast today from 9:00 to 11:00 a.m. EST by Cerevel Therapeutics (Nasdaq: CERE)

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). EYP-1901 leverages the Compan

Medscape, the leading source of clinical news, health information, continuing medical education, and point-of-care tools for healthcare professionals, together with collaborators including the United Nations COVID-19 Communications Response Initiative and leading global health experts, launched an educational learning center focused on advances in the prevention and management of COVID-19, including essential vaccine education.

Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care and prescription drug management system only for the Intended User, today announced that the Company has completed a $3 million fund raise with accredited investors, which represents the first third-party investment for the Company.

ANANDA Scientific and NYU Grossman School of Medicine Announce Second Clinical Trial Utilizing Liquid Structure TM Cannabidiol (CBD) for Evaluating Its Effect on Opioid Sparing in Participants with Chronic Radiculopathic Pain Syndromes